Template‐Derived Engineering of Peptide Inhibitors Targeting HSP90–CDC37 Interface: A Theoretical Framework for Cancer Therapeutics
Findings identify Pep14 derived from Template‐2 as a lead peptide candidate for disrupting the HSP90–CDC37 interaction, however, further experimental validation is required to confirm its therapeutic potential in cancer treatment.